Eli Lilly said its orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, opening a potential new growth avenue in the world's second-largest drug market. The update is supportive for Lilly's commercial outlook, while also highlighting intensifying competition with Novo Nordisk in GLP-1 therapies.
Eli Lilly said its orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, opening a potential new growth avenue in the world's second-largest drug market. The update is supportive for Lilly's commercial outlook, while also highlighting intensifying competition with Novo Nordisk in GLP-1 therapies.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
